Key clinical point: There is no standard for treatment discontinuation in multiple myeloma.
Major finding: The duration of therapy and time to next treatment were shorter in this study than in clinical trials, and reasons for treatment discontinuation varied by regimen and line of therapy.
Study details: An observational study of 3,201 multiple myeloma patients.
Disclosures: The study is sponsored by Takeda. Dr. Weisel reported relationships with Takeda and several other companies.
Weisel K et al. IMW 2019, Abstract OAB-005.